Kensuke Hikami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kensuke Hikami has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Arinobu Fukunaga
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
13 shared publications - Hiroyuki Sasanuma
Tokyo Metropolitan Institute of Medical Science 2 Genome Dynamics Project Tokyo, Japan
13 shared publications - Kei Mizuno
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
13 shared publications - Kodai Hattahara
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
13 shared publications - Osamu Ogawa
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
13 shared publications - Shusuke Akamatsu
Department of Urology Nagoya University Graduate School of Medicine Nagoya Japan
13 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
Supplementary Table 5 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
Supplementary Table 5 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
Prostate cancers harboring CDK12 alterations exhibit aggressive clinical behavior and poor responses to current therapeutic strategies. Although CDK12 is categorized as a homologous recombination repair (HRR)–related gene, clinical evidence indicates limited benefit of poly (ADP-ribose) polymerase (PARP) inhibitor monotherapy in CDK12-defective tumors. To clarify the functional consequences of CDK12 loss and identify a mechanistically rational therapeutic approach, we generated CDK12-knockout (KO) prostate cancer cell lines using CRISPR/Cas9 and assessed cell-cycle regulation, DNA damage repair, and replication stress via flow cytometry, γH2AX immunofluorescence, and DNA fiber assays. CDK12 KO abrogated the G0–G1 checkpoint, permitting cell-cycle progression into the M-phase despite the persistence of unrepaired DNA double-strand breaks (DSB), and reduced ATM transcription, resulting in a DSB response phenotype resembling ATM deficiency. CDK12 loss also increased intrinsic replication stress and sensitized prostate cancer cells to ATR inhibition. In patient-derived xenograft models harboring CDK12 alterations, combined PARP and ATR inhibition led to enhanced DSB accumulation and selectively suppressed tumor growth in CDK12-defective models. These findings highlight the importance of interrogating individual genes within the HRR pathway to define distinct mechanistic vulnerabilities and provide a strong rationale for combined PARP and ATR inhibition as a novel therapeutic strategy for patients with CDK12-altered prostate cancer.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
Prostate cancers harboring CDK12 alterations exhibit aggressive clinical behavior and poor responses to current therapeutic strategies. Although CDK12 is categorized as a homologous recombination repair (HRR)–related gene, clinical evidence indicates limited benefit of poly (ADP-ribose) polymerase (PARP) inhibitor monotherapy in CDK12-defective tumors. To clarify the functional consequences of CDK12 loss and identify a mechanistically rational therapeutic approach, we generated CDK12-knockout (KO) prostate cancer cell lines using CRISPR/Cas9 and assessed cell-cycle regulation, DNA damage repair, and replication stress via flow cytometry, γH2AX immunofluorescence, and DNA fiber assays. CDK12 KO abrogated the G0–G1 checkpoint, permitting cell-cycle progression into the M-phase despite the persistence of unrepaired DNA double-strand breaks (DSB), and reduced ATM transcription, resulting in a DSB response phenotype resembling ATM deficiency. CDK12 loss also increased intrinsic replication stress and sensitized prostate cancer cells to ATR inhibition. In patient-derived xenograft models harboring CDK12 alterations, combined PARP and ATR inhibition led to enhanced DSB accumulation and selectively suppressed tumor growth in CDK12-defective models. These findings highlight the importance of interrogating individual genes within the HRR pathway to define distinct mechanistic vulnerabilities and provide a strong rationale for combined PARP and ATR inhibition as a novel therapeutic strategy for patients with CDK12-altered prostate cancer.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) Schematic diagram of CDK12 genomic locus, target location, and gRNA sequence of the plasmid vector. B, Sanger sequencing chromatograms confirming the CDK12 knockout in clones CDK12KO#1–3. C, Cell Growth of LNCaP Parent and LNCaP CDK12KO#3 cells in vitro. Data represented as mean ± SEM. Statistical differences were determined by two-way repeated measures ANOVA followed by Bonferroni's post hoc tests. (n = 3/group in 2 unique experiments). D, Schematic diagram of CDK12 genomic locus, target location, and gRNA sequence of lentiviral vector. E, Western blotting of CDK12 protein in LNCaP Lenti-CTR#1–3 and LNCaP Lenti-CDK12KO#1–3. F, Cell Growth of 22RV1 Parent and 22RV1 CDK12KO#1-1, #1-2, #2-1, #2-2 cells in vitro. Data represented as mean ± SEM. Statistical differences were determined by two-way repeated measures ANOVA followed by Bonferroni's post hoc tests. (n = 3/group). G, The growth rate of LNCaP Parent and LNCaP CDK12KO#1–3 cells in the androgen-depleted medium. Data represented as mean ± SEM. Data were analyzed by one-way ANOVA with Tukey's post-hoc test for multiple comparisons. (n = 4/group). H, TP53 protein levels were knocked down using shRNA in LNCaP Parent and LNCaP CDK12KO cells, as confirmed by western blotting. I, (J) Effect of cyclin D1 overexpression (OE). Cyclin D1 was overexpressed in LNCaP Parent and LNCaP CDK12KO cells, as confirmed by western blotting (I). Tumor volume curves of subcutaneously implanted CDX in mice (n = 5 for each group) (J). Data represented as mean ± SEM. Differences between the CTR and cyclin D1 OE groups for each cell line were assessed using two-way repeated measures ANOVA with Bonferroni's post hoc tests. *, p < 0.05; **, p < 0.01 for cyclin D1 OE vs. CTR within the same cell line.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) Schematic diagram of CDK12 genomic locus, target location, and gRNA sequence of the plasmid vector. B, Sanger sequencing chromatograms confirming the CDK12 knockout in clones CDK12KO#1–3. C, Cell Growth of LNCaP Parent and LNCaP CDK12KO#3 cells in vitro. Data represented as mean ± SEM. Statistical differences were determined by two-way repeated measures ANOVA followed by Bonferroni's post hoc tests. (n = 3/group in 2 unique experiments). D, Schematic diagram of CDK12 genomic locus, target location, and gRNA sequence of lentiviral vector. E, Western blotting of CDK12 protein in LNCaP Lenti-CTR#1–3 and LNCaP Lenti-CDK12KO#1–3. F, Cell Growth of 22RV1 Parent and 22RV1 CDK12KO#1-1, #1-2, #2-1, #2-2 cells in vitro. Data represented as mean ± SEM. Statistical differences were determined by two-way repeated measures ANOVA followed by Bonferroni's post hoc tests. (n = 3/group). G, The growth rate of LNCaP Parent and LNCaP CDK12KO#1–3 cells in the androgen-depleted medium. Data represented as mean ± SEM. Data were analyzed by one-way ANOVA with Tukey's post-hoc test for multiple comparisons. (n = 4/group). H, TP53 protein levels were knocked down using shRNA in LNCaP Parent and LNCaP CDK12KO cells, as confirmed by western blotting. I, (J) Effect of cyclin D1 overexpression (OE). Cyclin D1 was overexpressed in LNCaP Parent and LNCaP CDK12KO cells, as confirmed by western blotting (I). Tumor volume curves of subcutaneously implanted CDX in mice (n = 5 for each group) (J). Data represented as mean ± SEM. Differences between the CTR and cyclin D1 OE groups for each cell line were assessed using two-way repeated measures ANOVA with Bonferroni's post hoc tests. *, p < 0.05; **, p < 0.01 for cyclin D1 OE vs. CTR within the same cell line.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) Schematic diagram of experimental design of flow cytometry for Fig. 2A. B, (C) Pulse-chase analysis. Schematic diagram of experimental design (B), and the percentage of cells that entered the S phase(C). Data represented as mean ± SEM. Significant differences were determined by one-way ANOVA with Tukey's post-hoc test for multiple comparisons. (n = 3, 2 unique experiments) (D) Schematic diagram of experimental design for Fig. 2B. E, Schematic diagram of experimental design for Fig. 2C, 2D.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) Schematic diagram of experimental design of flow cytometry for Fig. 2A. B, (C) Pulse-chase analysis. Schematic diagram of experimental design (B), and the percentage of cells that entered the S phase(C). Data represented as mean ± SEM. Significant differences were determined by one-way ANOVA with Tukey's post-hoc test for multiple comparisons. (n = 3, 2 unique experiments) (D) Schematic diagram of experimental design for Fig. 2B. E, Schematic diagram of experimental design for Fig. 2C, 2D.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) mRNA expression of ATR, BLM, BRCA1, FANCD2, and FANCI in LNCaP Parent and LNCaP CDK12KO#1,2 cells measured by quantitative RT–PCR. Data are normalized to GAPDH and presented as mean ± SEM (n = 3 independent experiments). B, (C) Expression of indicated exons of the ATM gene in LNCaP Parent and LNCaP CDK12KO#1–3 cells(B), in KUCaP12, 18, and 21(C), measured by quantitative RT–PCR. Data are normalized to GAPDH and presented as mean ± SEM (n = 3 independent experiments). D, Western blot analysis of ATM in 22RV1 Lenti-CTR and 22RV1 Lenti-CDK12KO#1-1, 1 to 2, 2-1, 2-2 cells. E, Schematic diagram of experimental design for Fig. 3D. F, (J) Representative immunofluorescence images from the experiment in Fig. 3D. F, Zoomed-in image of a single nucleus, (J) Whole field (400x magnification). G, Schematic diagram of experimental design for Fig. 3E. H, (K) Representative immunofluorescence images from the experiment in Fig. 3E.(H) Zoomed-in image of a single nucleus, (K) Whole field (400x magnification). I, Schematic diagram of experimental design for Fig. 3F. (L) Representative immunofluorescence images from the experiment in Fig. 3H. (M) Western blot analysis of indicated proteins in LNCaP Parent, LNCaP CDK12KO#1-3, and LNCaP Parent treated with THZ531.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) mRNA expression of ATR, BLM, BRCA1, FANCD2, and FANCI in LNCaP Parent and LNCaP CDK12KO#1,2 cells measured by quantitative RT–PCR. Data are normalized to GAPDH and presented as mean ± SEM (n = 3 independent experiments). B, (C) Expression of indicated exons of the ATM gene in LNCaP Parent and LNCaP CDK12KO#1–3 cells(B), in KUCaP12, 18, and 21(C), measured by quantitative RT–PCR. Data are normalized to GAPDH and presented as mean ± SEM (n = 3 independent experiments). D, Western blot analysis of ATM in 22RV1 Lenti-CTR and 22RV1 Lenti-CDK12KO#1-1, 1 to 2, 2-1, 2-2 cells. E, Schematic diagram of experimental design for Fig. 3D. F, (J) Representative immunofluorescence images from the experiment in Fig. 3D. F, Zoomed-in image of a single nucleus, (J) Whole field (400x magnification). G, Schematic diagram of experimental design for Fig. 3E. H, (K) Representative immunofluorescence images from the experiment in Fig. 3E.(H) Zoomed-in image of a single nucleus, (K) Whole field (400x magnification). I, Schematic diagram of experimental design for Fig. 3F. (L) Representative immunofluorescence images from the experiment in Fig. 3H. (M) Western blot analysis of indicated proteins in LNCaP Parent, LNCaP CDK12KO#1-3, and LNCaP Parent treated with THZ531.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) Schematic diagram of ATM genomic locus, target location, and gRNA sequence. B, Schematic diagram of experimental design for Fig 4A. C, Schematic diagram of experimental design for Fig 4B. D, Combination index (CI) analysis. The drug concentration is plotted on the x-axis against the CI value on the y-axis. A CI value less than 1 (<1) indicates a synergistic effect of the drug combination. The ratio of VE821 and Olaparib was fixed at 1:2.25.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) Schematic diagram of ATM genomic locus, target location, and gRNA sequence. B, Schematic diagram of experimental design for Fig 4A. C, Schematic diagram of experimental design for Fig 4B. D, Combination index (CI) analysis. The drug concentration is plotted on the x-axis against the CI value on the y-axis. A CI value less than 1 (<1) indicates a synergistic effect of the drug combination. The ratio of VE821 and Olaparib was fixed at 1:2.25.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) (B) Clinical course of patients from which the KUCaP18 (A) and KUCaP21 (B) patient-derived xenograft models were established. (iPSA, initial prostate-specific antigen; AA, anti-androgen therapy; ENZ, enzalutamide; ABI, abiraterone; DTX, docetaxel; LHRH, luteinizing hormone-releasing hormone; TUR-P, trans-urethral resection of prostate; LN, lymph node)(C) mRNA expression of ATR, BRCA1, BRCA2, BLM, FANCD2, and FANCI in KUCaP12, 18, 21 measured by quantitative RT–PCR. Gene expression normalized to GAPDH and shown relative to the KUCaP12 strain. Data are presented as mean ± SEM (n = 3).
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) (B) Clinical course of patients from which the KUCaP18 (A) and KUCaP21 (B) patient-derived xenograft models were established. (iPSA, initial prostate-specific antigen; AA, anti-androgen therapy; ENZ, enzalutamide; ABI, abiraterone; DTX, docetaxel; LHRH, luteinizing hormone-releasing hormone; TUR-P, trans-urethral resection of prostate; LN, lymph node)(C) mRNA expression of ATR, BRCA1, BRCA2, BLM, FANCD2, and FANCI in KUCaP12, 18, 21 measured by quantitative RT–PCR. Gene expression normalized to GAPDH and shown relative to the KUCaP12 strain. Data are presented as mean ± SEM (n = 3).
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) Five-week dosing experiments of another ATR inhibitor (Bay1895344) and Olaparib combination using KUCaP18 and 21 PDX models. Data represented as mean ± SEM. Data were analyzed using a linear mixed model (LMM). Post hoc pairwise comparisons were performed on the model estimates with Bonferroni's method. (n = 5 mice per group). *, p < 0.05; **, p < 0.01; ***, p < 0.001. The KUCaP18 study was terminated at the 4-week time point due to excessive tumor growth in the Vehicle group. B, (C) After dosing experiments, tumors were harvested on the day after the final day of treatment. Western blotting of γH2AX protein in each group and percent of γH2AX protein level per β-actin measured using ImageJ for KUCaP18 (B) and KUCaP21 (C). Data represented as mean ± SEM. Welch's t-test. D, Five-week dosing experiments of another ATR inhibitor (AZD6738) and Olaparib combination using KUCaP18. Data represented as mean ± SEM. Data were analyzed using a linear mixed model (LMM). Post hoc pairwise comparisons were performed on the model estimates with Bonferroni's method. (n = 6 mice per group). **, p < 0.01; ***, p < 0.001. E, (F) (G) Changes in body weight of mice during dosing experiments. Fig 6A(E); Fig S6A(F); Fig S6D(G). Data represented as mean ± SEM. Data were analyzed by one-way ANOVA.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
(A) Five-week dosing experiments of another ATR inhibitor (Bay1895344) and Olaparib combination using KUCaP18 and 21 PDX models. Data represented as mean ± SEM. Data were analyzed using a linear mixed model (LMM). Post hoc pairwise comparisons were performed on the model estimates with Bonferroni's method. (n = 5 mice per group). *, p < 0.05; **, p < 0.01; ***, p < 0.001. The KUCaP18 study was terminated at the 4-week time point due to excessive tumor growth in the Vehicle group. B, (C) After dosing experiments, tumors were harvested on the day after the final day of treatment. Western blotting of γH2AX protein in each group and percent of γH2AX protein level per β-actin measured using ImageJ for KUCaP18 (B) and KUCaP21 (C). Data represented as mean ± SEM. Welch's t-test. D, Five-week dosing experiments of another ATR inhibitor (AZD6738) and Olaparib combination using KUCaP18. Data represented as mean ± SEM. Data were analyzed using a linear mixed model (LMM). Post hoc pairwise comparisons were performed on the model estimates with Bonferroni's method. (n = 6 mice per group). **, p < 0.01; ***, p < 0.001. E, (F) (G) Changes in body weight of mice during dosing experiments. Fig 6A(E); Fig S6A(F); Fig S6D(G). Data represented as mean ± SEM. Data were analyzed by one-way ANOVA.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
Supplementary Table 1 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
Supplementary Table 1 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
Supplementary Table 3 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency
Supplementary Table 3 from Dual Inhibition of PARP and ATR Induces Synthetic Lethal Vulnerability in Prostate Cancer with CDK12 Deficiency